Nicotinamide Riboside in Systolic Heart Failure

Sponsor: University of Washington
Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Purpose

Mitochondrial Randomize participants with systolic hart failure (HF) to treatment with NAD precursor, nicotinamide riboside(NR) or matching placebo, to determine the safety and tolerability of NR in participants with systolic HF.

Study Design

Triple masked,2:1 randomization to NR vs matching placebo

Dose

Uptitrated to final dose of 1000mg 2x daily starting at 250mg and achieving 1000mg 2x daily by end of week 4

Length of Intervention

12 weeks

Intrinsic Capacity

Vitality

Status

Completed

Condition or Disease 

Heart Failure, Systolic

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Vitality, CompletedANAD Staff